长春高新：子公司注射用GenSci143境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of GenSci143 in patients with advanced solid tumors [1] Group 1: Company Developments - Jinsai Pharmaceutical has been granted a Clinical Trial Approval Notice for GenSci143, a first-class therapeutic biological product developed independently by the company [1] - The clinical trial will focus on advanced solid tumors, specifically targeting prostate cancer and lung cancer among other indications [1]